What is Soltamox (tamoxifen)?
Soltamox (tamoxifen) is an anti-estrogen that prevents the effects of estrogens on tissues and is used to treat invasive breast cancer in men and women, the most common type of breast cancer, following surgery and/or radiation and to prevent invasive breast cancer in women at high risk for developing it.
Soltamox also is used to treat women following surgery and radiation for a less common type of breast cancer called ductal carcinoma in situ (DCIS or intraductal carcinoma).
Women who have had DCIS are at high risk for developing invasive breast cancer at a later date, and Soltamox prevents development of the invasive cancer in almost half of the women during the first five years of treatment. Occasionally, Soltamox is used to stimulate ovulation.
Common side effects of Soltamox include:
- hot flashes,
- weight loss,
- abnormal or absence of menstrual periods,
- vaginal discharge,
- vaginal bleeding,
- lightheadedness,
- dizziness,
- headache,
- vomiting,
- nausea,
- cough,
- fatigue,
- fluid retention,
- bone pain,
- cataracts, and
- depression.
Serious side effects of Soltamox include blood clots leading to:
- deep vein thrombosis (DVT) and pulmonary embolism (PE),
- abnormalities of liver tests,
- reduced white blood cells,
- red blood cells, and
- platelets. Reduced platelets can lead to bleeding.
Drug interactions of Soltamox include warfarin, because Soltamox increases its blood-thinning effects.
Soltamox reduces blood levels of letrozole and anastrozole.
Phenobarbital and rifampin may reduce blood levels of Soltamox by increasing the breakdown of Soltamox.
Soltamox should not be used during pregnancy because it can harm a fetus. It is unknown if Soltamox is excreted in breast milk. Soltamox causes a reduction in milk production. Women taking Soltamox should not breastfeed.
What are the important side effects of Soltamox (tamoxifen)?
WARNING
Uterine malignancies, stroke, and pulmonary embolism were reported when tamoxifen was used for risk-reduction in women with ductal carcinoma in situ and women at high risk for breast cancer.
The most common side effects associated with tamoxifen are:
- Hot flashes
- Weight loss
- Abnormal or absence of menstrual periods
- Vaginal discharge
- Vaginal bleeding
- Lightheadedness
- Dizziness
- Headache
- Vomiting
- Nausea
- Cough
- Fatigue
- Fluid retention
- Bone pain
- Cataracts
- Depression
Serious side effects include:
- Tamoxifen is associated with blood clots leading to deep vein thrombosis and pulmonary embolism.
- Tamoxifen can cause abnormalities of liver tests, reduced white blood cells, red blood cells, and platelets. Reduced platelets can lead to bleeding. Patients should keep appointments for blood work to monitor for these side effects. Patients should report any suspected side effects immediately, especially bleeding and yellowing of the skin.
Soltamox (tamoxifen) side effects list for healthcare professionals
The following serious adverse reactions are discussed below and elsewhere in the labeling:
- Uterine malignancies
- Thromboembolic events
- Embryo-Fetal Toxicity
- Liver cancer
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adverse Reactions In Patients With Metastatic Breast Cancer
In patients treated with tamoxifen for metastatic breast cancer, the most frequent adverse reaction was hot flashes. Other adverse reactions which were seen less commonly are:
- hypercalcemia,
- peripheral edema,
- distaste for food,
- pruritus vulvae,
- depression,
- dizziness,
- lightheadedness,
- headache,
- hair thinning and/or partial hair loss, and
- vaginal dryness.
Increased bone, tumor pain and local disease flare have occurred. Patients with soft tissue disease may have sudden increases in the size of preexisting lesions, sometimes associated with marked erythema within and surrounding the lesions and/or the development of new lesions. When they occurred, the bone pain or disease flares were seen shortly after starting tamoxifen and generally subsided rapidly.
Premenopausal Women With Metastatic Breast Cancer
Table 1 summarizes the incidence of adverse reactions reported at a frequency of 2% or greater from clinical trials that compared tamoxifen therapy to ovarian ablation in premenopausal patients with metastatic breast cancer.
Table 1: Adverse Reactions (frequency ≥2% in either arm) from Trials Comparing Tamoxifen to Ovarian Ablation in Premenopausal Women with Metastatic Breast Cancer
% of Women | ||
Tamoxifen N=104 | Ovarian Ablation N=100 | |
Adverse Reactions* | ||
Flush | 33 | 46 |
Amenorrhea | 16 | 69 |
Altered menses | 13 | 5 |
Oligomenorrhea | 9 | 1 |
Bone pain | 6 | 6 |
Menstrual disorder | 6 | 4 |
Nausea | 5 | 4 |
Cough/coughing | 4 | 1 |
Edema | 4 | 1 |
Fatigue | 4 | 1 |
Musculoskeletal pain | 3 | 0 |
Pain | 3 | 4 |
Ovarian cyst(s) | 3 | 2 |
Depression | 2 | 2 |
Abdominal cramps | 1 | 2 |
Anorexia | 1 | 2 |
* Some women had more than one adverse reaction. |
Adverse Reactions In Adjuvant Breast Cancer
In the NSABP B-14 study, women with axillary node-negative breast cancer were randomized to 5 years of tamoxifen 20 mg per day or placebo following primary surgery. Table 2 presents the most common adverse reactions (mean follow-up of approximately 6.9 years) that were more common on tamoxifen than placebo.
Table 2: Most Common Adverse Reactions in Women with Axillary Node-Negative Breast Cancer (Study NSABP B-14)
% of women | ||
Tamoxifen N = 1,422 | Placebo N = 1,437 | |
Hot flashes | 64 | 48 |
Fluid retention | 32 | 30 |
Vaginal discharge | 30 | 15 |
Nausea | 26 | 24 |
Irregular menses | 25 | 19 |
Weight loss (> 5%) | 23 | 18 |
Skin changes | 19 | 15 |
Increased SGOT | 5 | 3 |
Increased bilirubin | 2 | 1 |
Increased creatinine | 2 | 1 |
Thrombocytopenia* | 2 | 1 |
Thrombotic events** | ||
Deep vein thrombosis | 0.8 | 0.2 |
Pulmonary embolism | 0.5 | 0.2 |
Superficial phlebitis | 0.4 | 0 |
* Defined as a platelet count of < 100,000/mm³ **Two of the tamoxifen-treated patients who had thrombotic events died. |
In the Eastern Cooperative Oncology Group (ECOG) adjuvant breast cancer trial, tamoxifen or placebo was administered for 2 years to women following mastectomy. When compared to placebo, tamoxifen showed a higher incidence of hot flashes (19% vs. 8% for placebo). The incidence of all other adverse reactions was similar in the two treatment groups with the exception of thrombocytopenia, where the incidence for tamoxifen was 10% vs. 3% for placebo.
In other adjuvant studies [the Toronto study and Tamoxifen Adjuvant Trial Organization (NATO)], women received either tamoxifen or no therapy. In the Toronto study, hot flashes were observed in 29% of patients for tamoxifen vs. 1% in the untreated group. In the NATO trial, hot flashes and vaginal bleeding were reported in 2.8% and 2.0% of women, respectively, for tamoxifen vs. 0.2% for each in the untreated group.
Anastrozole Adjuvant Trial (ATAC: Arimidex, Tamoxifen, Alone Or In Combination) - Study Of Anastrozole Compared To Tamoxifen For Adjuvant Treatment Of Early Breast Cancer
At a median follow-up of 33 months, the combination of anastrozole and tamoxifen did not demonstrate an efficacy benefit when compared to tamoxifen monotherapy in all patients as well as in the hormone receptorpositive subpopulation. The combination treatment arm was discontinued from the trial. The median duration of adjuvant treatment for safety evaluation was 59.8 months and 59.6 months for patients receiving anastrozole 1 mg and tamoxifen 20 mg monotherapy, respectively.
Adverse reactions occurring with an incidence of at least 5% in either single-drug treatment group during treatment or within 14 days of the end of treatment are presented in Table 3.
Table 3: Adverse Reactions Occurring with an Incidence of at Least 5% in Either Single-Drug Treatment Group During Treatment or Within 14 Days of the End of Treatment in the ATAC Trial
Body system and adverse reactions by COSTART-preferred term* | % of Women | |
Tamoxifen N = 3,094 | Anastrozole N = 3,092 | |
Body as a whole | ||
Asthenia | 18 | 19 |
Pain | 16 | 17 |
Back pain | 10 | 10 |
Accidental injury | 10 | 10 |
Abdominal pain | 9 | 9 |
Infection | 9 | 9 |
Headache | 8 | 10 |
Flu syndrome | 6 | 6 |
Cyst | 5 | 5 |
Chest pain | 5 | 7 |
Neoplasm | 5 | 5 |
Cardiovascular | ||
Vasodilatation | 41 | 36 |
Hypertension | 11 | 13 |
Digestive | ||
Nausea | 11 | 11 |
Constipation | 8 | 8 |
Diarrhea | 7 | 9 |
Dyspepsia | 6 | 7 |
Gastrointestinal disorder | 5 | 7 |
Hemic and lymphatic | ||
Lymphedema | 11 | 10 |
Anemia | 5 | 4 |
Metabolic and nutritional | ||
Peripheral edema | 11 | 10 |
Weight gain | 9 | 9 |
Hypercholesterolemia | 3 | 9 |
Musculoskeletal | ||
Arthritis | 14 | 17 |
Arthralgia | 11 | 15 |
Osteoporosis | 7 | 11 |
Fracture | 7 | 10 |
Bone pain | 6 | 7 |
Joint disorder | 5 | 6 |
Myalgia | 5 | 6 |
Arthrosis | 5 | 7 |
Nervous system | ||
Depression | 12 | 13 |
Insomnia | 9 | 10 |
Dizziness | 8 | 8 |
Anxiety | 6 | 6 |
Paresthesia | 5 | 7 |
Respiratory | ||
Pharyngitis | 14 | 14 |
Cough increased | 9 | 8 |
Dyspnea | 8 | 8 |
Sinusitis | 5 | 6 |
Bronchitis | 5 | 5 |
Skin and appendages | ||
Rash | 13 | 11 |
Sweating | 6 | 5 |
Special senses | ||
Cataract specified | 7 | 6 |
Urogenital | ||
Urinary tract infection | 10 | 8 |
Leukorrhea | 9 | 3 |
Vaginal hemorrhage† | 6 | 4 |
Breast pain | 6 | 8 |
Vaginitis | 5 | 4 |
Vulvovaginitis | 5 | 6 |
Breast neoplasm | 5 | 5 |
* COSTART: Coding Symbols for Thesaurus of Adverse Reaction Terms. A patient may have had more than 1 adverse reaction, including more than 1 adverse reaction in the same body system. † Vaginal hemorrhage without further diagnosis |
Certain adverse reactions and combinations of adverse reactions were prospectively specified for analysis in the ATAC trial, based on the known pharmacologic properties and safety profiles of the two drugs (Table 4).
Table 4: Percentage of Patients with Pre-Specified Adverse Reactions in the ATAC Triala
% of Women | Odds Ratioc | 95% CI | ||
Tamoxifen N = 3,094 | Anastrozole N = 3,092 | |||
Hot flashes | 41 | 36 | 0.80 | 0.73 to 0.89 |
Musculoskeletal eventsb | 29 | 36 | 1.32 | 1.19 to 1.47 |
Mood disturbances | 18 | 19 | 1.10 | 0.97 to 1.25 |
Fatigue/asthenia | 18 | 19 | 1.07 | 0.94 to 1.22 |
Vaginal discharge | 13 | 4 | 0.24 | 0.19 to 0.30 |
Nausea and vomiting | 12 | 13 | 1.03 | 0.88 to 1.19 |
Vaginal bleeding | 10 | 5 | 0.50 | 0.41 to 0.61 |
Cataracts | 7 | 6 | 0.85 | 0.69 to 1.04 |
All fractures | 7 | 10 | 1.57 | 1.30 to 1.88 |
Fractures of spine, hip, or wrist | 3 | 4 | 1.48 | 1.13 to 1.95 |
Wrist/Colles’ fractures | 2 | 2 | ||
Hip fractures | 1 | 1 | ||
Spine fractures | 1 | 1 | ||
Venous thromboembolic events | 5 | 3 | 0.61 | 0.47 to 0.80 |
Deep venous thromboembolic events | 2 | 2 | 0.64 | 0.45 to 0.93 |
Ischemic cerebrovascular events | 3 | 2 | 0.70 | 0.50 to 0.97 |
Ischemic cardiovascular | 3 | 4 | 1.23 | 0.95 to 1.60 |
disease | ||||
Endometrial cancerd | 0.6 | 0.2 | 0.31 | 0.10 to 0.94 |
a Patients with multiple events in the same category are counted only once in that category. b Refers to joint symptoms, including joint disorder, arthritis, arthrosis and arthralgia. c The odds ratios <1 favor anastrozole and those >1 favor tamoxifen. d Percentages calculated based upon the numbers of women who had not undergone hysterectomy at baseline. |
Adverse Reactions In Ductal Carcinoma In Situ
The types and frequency of adverse reactions in the NSABP B-24 trial in women with DCIS were consistent with those observed in the other adjuvant trials conducted with tamoxifen.
Adverse Reactions In Women At High Risk For Breast Cancer
In the NSABP P-1 trial, there was an increase in five serious adverse reactions in the tamoxifen group:
- endometrial cancer (33 cases in the tamoxifen group vs. 14 in the placebo group);
- pulmonary embolism (18 cases in the tamoxifen group vs. 6 in the placebo group);
- deep vein thrombosis (30 cases in the tamoxifen group vs. 19 in the placebo group);
- stroke (34 cases in the tamoxifen group vs. 24 in the placebo group);
- cataract formation (540 cases in the tamoxifen group vs. 483 in the placebo group), and
- cataract surgery (101 cases in the tamoxifen group vs. 63 in the placebo group).
Table 5 presents the adverse reactions observed in NSABP P-1 by treatment arm. Only adverse reactions more common on tamoxifen than placebo are shown.
Table 5: Most Common Adverse Reactions in Women at High Risk for Breast Cancer (Study NSABP P-1)
% of Women | ||
Tamoxifen N = 6,681 | Placebo N = 6,707 | |
Self-Reported Symptoms | N = 6,441a | N = 6,469a |
Hot flashes | 80 | 68 |
Vaginal discharge | 55 | 35 |
Vaginal bleeding | 23 | 22 |
Laboratory Abnormalities | N = 6,520b | N = 6,535b |
Platelets decreased | 0.7 | 0.3 |
Adverse Reactions | N = 6,492c | N = 6,484c |
Mood changes | 11.6 | 10.8 |
Infection/sepsis | 6.0 | 5.1 |
Constipation | 4.4 | 3.2 |
Skin changes | 5.6 | 4.7 |
Alopecia | 5.2 | 4.4 |
Allergy | 2.5 | 2.1 |
a Number with quality of life questionnaires b Number with treatment follow-up forms c Number with adverse drug reaction forms |
In the NSABP P-1 trial, 15.0% and 9.7% of participants receiving tamoxifen and placebo therapy, respectively, withdrew from the trial for medical reasons including the following: hot flashes (3.1% vs. 1.5%, respectively) and vaginal discharge (0.5% vs. 0.1% respectively).
Severe hot flashes occurred in 28% of women on placebo and 45% of women on tamoxifen. Vaginal discharge was severe in 4.5% on placebo and 12.3% on tamoxifen.
Soltamox-related Adverse Reactions
In a single-dose pharmacokinetic study in healthy perimenopausal and postmenopausal women, throat irritation was reported by 3 of 60 evaluable subjects (5%) in the Soltamox treatment group while none of the subjects in the tamoxifen citrate tablet group reported this event. All cases were mild, occurred within an hour after dosing, and resolved within 24 hours.
Postmarketing Experience
The following adverse reactions have been identified during postapproval use of tamoxifen. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Skin and Subcutaneous Disorders: Erythema multiforme, Stevens-Johnson syndrome, bullous pemphigoid
Respiratory, Thoracic, Mediastinal Disorders: Interstitial pneumonitis
Immune System Disorders: Hypersensitivity reactions including angioedema; in some of these cases, the time to onset was more than one year.
Gastrointestinal Disorders: Elevation of serum triglyceride levels, in some cases with pancreatitis
Men With Metastatic Breast Cancer
Loss of libido and impotence have resulted in discontinuation of tamoxifen therapy in male patients. In oligospermic males treated with tamoxifen, LH, FSH, testosterone, and estrogen levels were elevated, with no reported associated clinical changes.
What drugs interact with Soltamox (tamoxifen)?
Aromatase Inhibitors
Anastrozole
The combination of anastrozole and tamoxifen did not demonstrate any benefit when compared to tamoxifen alone and should be avoided in all patients. In the ATAC trial, co-administration of anastrozole and tamoxifen in breast cancer patients reduced the anastrozole plasma concentration by 27% compared to that achieved with anastrozole alone. The tamoxifen concentration was not altered.
Letrozole
The concomitant use of letrozole with tamoxifen is not recommended because the efficacy of the combination in the adjuvant treatment of breast cancer has not been established. Tamoxifen reduced the plasma concentration of letrozole by 38% when these drugs were co-administered.
Warfarin
A marked increase in anticoagulant effect may occur when tamoxifen is used in combination with warfarin. Closely monitor coagulation indices in patients who are taking tamoxifen for either the treatment of metastatic breast cancer or as adjuvant therapy who require concomitant use of warfarin.
Inducers Of CYP3A4
Strong CYP3A4 inducers should not be used with tamoxifen. Strong CYP3A4 inducers (e.g., rifampin) reduce tamoxifen AUC and Cmax.
Strong Inhibitors Of CYP2D6
The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. Some studies have shown that the efficacy of tamoxifen may be reduced when the drugs are co-administered as a result of reduced levels of potent active metabolites of tamoxifen. However, other studies have failed to demonstrate such an effect.
Drug-Laboratory Test Interactions
There are postmarketing reports of T4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. These elevations were not accompanied by clinical hyperthyroidism.
Variations in the karyopyknotic index on vaginal smears and various degrees of estrogen effect on Pap smears have been seen in postmenopausal patients taking tamoxifen.
Summary
Soltamox (tamoxifen) is an anti-estrogen that prevents the effects of estrogens on tissues and is used to treat invasive breast cancer in men and women, the most common type of breast cancer, following surgery and/or radiation and to prevent invasive breast cancer in women at high risk for developing it. Common side effects of Soltamox include hot flashes, weight loss, abnormal or absence of menstrual periods, vaginal discharge, vaginal bleeding, lightheadedness, dizziness, headache, vomiting, nausea, cough, fatigue, fluid retention, bone pain, cataracts, and depression. Soltamox should not be used during pregnancy because it can harm a fetus. It is unknown if Soltamox is excreted in breast milk. Soltamox causes a reduction in milk production. Women taking Soltamox should not breastfeed.
Multimedia: Slideshows, Images & Quizzes
-
Breast Cancer Awareness: Symptoms, Diagnosis, and Treatment
Learn about breast cancer causes, symptoms, tests, recovery, and prevention. Discover the types of treatments such as surgery and...
-
10 Things Young Women Should Know About Breast Cancer
Is breast cancer genetic? Should I get tested for the BRCA gene? What every young women should know about breast cancer. Discover...
-
Breast Cancer Quiz: Symptoms & Signs
This Breast Cancer Quiz features signs, symptoms, facts, causes, common forms, terms, risk factors, statistics, and more. ...
-
Breast Cancer: Where It Can Spread
When breast cancer spreads, or metastasizes, it often goes to these five places: the lymph nodes, bones, liver, lungs, and brain....
Related Disease Conditions
-
Breast Cancer in Men
Second Source WebMD Medical Reference
-
Male Breast Cancer
Male breast cancer accounts for 1% of all breast cancers, and most cases are found in men between the ages of 60 and 70. A man's risk of developing breast cancer is one in 1,000. Signs and symptoms include a firm mass located below the nipple and skin changes around the nipple, including puckering, redness or scaling, retraction and ulceration of the nipple. Treatment depends upon staging and the health of the patient.
-
Triple-Negative Breast Cancer
Triple-negative breast cancer is more common in Hispanic and African-American women. Signs and symptoms include a lump in the armpit or breast, nipple discharge and inversion, and changes in the breast's skin. Treatment may incorporate surgery, chemotherapy, and radiation therapy.
-
Breast Cancer
Breast cancer is an invasive tumor that develops in the mammary gland. Breast cancer is detected via mammograms, breast self-examination (BSE), biopsy, and specialized testing on breast cancer tissue. Treatment of breast cancer may involve surgery, radiation, hormone therapy, chemotherapy, and targeted therapy. Breast cancer risk may be lowered by managing controllable risk factors. What you should know about breast cancer Breast cancer is the most common cancer among American women. One in every eight women in the United States develops breast cancer. There are many types of breast cancer that differ in their capability of spreading (metastasize) to other body tissues. The causes of breast cancer are unknown, although medical professionals have identified a number of risk factors. There are 11 common types of breast cancer and 4 uncommon types of breast cancer. Breast cancer early signs and symptoms include a lump in the breast or armpit, bloody nipple discharge, inverted nipple, orange-peel texture or dimpling of the breast's skin (peau d'orange), breast pain or sore nipple, swollen lymph nodes in the neck or armpit, and a change in the size or shape of the breast or nipple. Breast cancer can also be symptom free, which makes following national screening recommendations an important practice. Breast cancer is diagnosed during a physical exam, by a self-exam of the breasts, mammography, ultrasound testing, and biopsy. Treatment of breast cancer depends on the type of cancer and its stage (0-IV) and may involve surgery, radiation, or chemotherapy.
-
Inflammatory Breast Cancer
Inflammatory breast cancer is an accelerated form of breast cancer that is not usually detected by mammogram or ultrasound. Symptoms of inflammatory breast cancer include pain in the breast, skin change in the breast area, bruise on the breast,sudden swelling of the breast, nipple retraction or discharge, and swelling of the lymph nodes.
-
Breast Cancer Prevention
Lifestyle changes, a healthy antioxidant-rich diet, exercise, and weight reduction can help reduce a woman's risk of developing breast cancer. It's important to be aware of how risk factors such as family history, lifestyle factors, breast conditions, radiation therapy, and hormonal factors may influence your chances of developing breast cancer. Mammography and breast self-examinations are crucial steps in breast cancer prevention.
-
Breast Cancer and Lymphedema
Lymphedema is a common chronic, debilitating condition in which excess fluid called lymph collects in tissues and causes swelling in them. It is common after a mastectomy, lumpectomy or breast cancer surgery and radiation therapy.
-
Breast Cancer and Coping With Stress
Being diagnosed with breast cancer is stressful. Learning relaxation techniques, exercising, eating well, getting adequate sleep, receiving psychotherapy, and maintaining a positive attitude can help you cope. Creating documents, such as an advance directive, living will, and durable power of attorney will outline your wishes in the event that you are no longer able to make decisions regarding your care.
-
Breast Cancer Recurrence
Breast cancer most often recurs within the first 3-5 years after the initial treatment. Changes in the look, feel, or appearance of the breast may indicate breast cancer recurrence. Factors related to recurrence include tumor size, tumor grade, hormone receptor status, lymph node involvement, and oncogene expression. Check out the center below for more medical references on breast cancer, including multimedia (slideshows, images, and quizzes), related diseases, treatment, diagnosis, medications, and prevention or wellness.
-
Breast Cancer Early Warning Signs and Symptoms
In most cases, there are no early warning signs of breast cancer. Breast cancer may not produce any early symptoms, and in many cases, it is first discovered on screening mammography. The most common sign of breast cancer is a new lump or mass in the breast.
-
Breast Cancer Stages
Breast cancer staging is the determination of the extent and spread of cancer. An individual's health care team uses stages to summarize the extent of cancer in a standardized way that is recognized by all health care providers. They use this staging to determine the treatment most appropriate for the type of cancer. Cancer staging helps to determine the prognosis, or outlook, of cancer, including rates of recurrence and survival rates.
-
What Should I Know About Breast Cancer?
Breast cancer is the most common non-skin cancer of American women, but it can also occur in men. Every year in the U.S., there are over 266,000 new diagnoses of breast cancer. A woman has a risk of one in eight for developing breast cancer at some point during her lifetime.
-
HER2-Positive Breast Cancer
In about 10%-20% of breast cancers, the cancer cells test positive for HER2, sometimes referred to as the HER2/neu protein. HER2 is a growth-promoting protein located on the surface of some cancer cells. HER2-positive breast cancers tend to grow more rapidly and spread more aggressively than breast cancers that are HER2-negative. Doctors do not know what specifically causes some breast cancers to express this protein while others do not.
-
Breast Cancer Treatment by Stage
Treatment of breast cancer depends upon the stage of the cancer at the time of diagnosis. Some of the various treatments include: hormone therapy, radiation therapy, surgery, chemotherapy, HER2-targeted therapy, neoadjuvant therapy, and adjuvant therapy.
-
Breast Cancer Treatment
Breast cancer treatments depend upon the type of breast cancer that is present as well as the stage (extent of spread) of the tumor. Treatment for early breast cancer typically involves surgery to remove the tumor. After surgery, medical professionals may administer radiation therapy, chemotherapy, or targeted therapy.
-
What Is the Breast Cancer BRCA Gene Test?
BRCA genes (BRCA 1 and 2, when normal, repair damaged DNA) are among the genetic mutations linked to breast cancer, ovarian cancer, and other cancers when mutated. Every woman with a BRCA mutation is at high risk for breast cancer, irrespective of whether she has a family history of breast cancer or not. By age 80, a woman with a BRCA mutation has about an 80% chance of developing breast cancer. BRCA1 and BRCA2 gene mutations also increase the risk of ovarian cancer, by 54% and 23%, respectively.
-
What Questions Should I Ask My Doctor About Breast Cancer?
A diagnosis of breast cancer can be overwhelming, so it's important to write down all your questions before meeting with your doctor.
-
Breast Cancer During Pregnancy
Breast cancer occurs in about 1 in every 1,000 pregnant women. Treatment of breast cancer during pregnancy involves surgery, but it is very difficult to protect the baby from the dangerous effects of radiation and chemotherapy. It can be an agonizing to decide whether or not to undergo breast cancer treatment while one is pregnant.
-
Breast Cancer in Young Women
About 5% of cases of breast cancer occur in women under the age of 40 years old. Some risk factors for breast cancer in young women include a personal history of breast cancer or breast disease, family history of breast cancer, prior radiation therapy, and the presence of BRCA1/BRCA2 gene mutations. Breast self-exams, clinical breast exams, and screening mammograms may help detect breast cancer. Treatment may include surgery, chemotherapy, radiation, and hormone therapy.
-
Breast Cancer Clinical Trials
Breast cancer clinical trials are research programs designed to evaluate new medical treatments, drugs, or devices for the treatment of breast cancer. Clinical trials are designed to test the safety and efficacy of new treatments as well as assess potential side effects. Clinical trials also compare new treatment to existing treatments to determine if it's any better. There are many important questions to ask your doctor before taking part in a breast cancer clinical trial.
-
Genetic Testing: Families With Breast Cancer
Breast cancer can be a killer and the decision to get tested to see if a patient is prone to the disease should be discussed with a doctor -- particularly if the woman has a history of breast cancer in her family. Genetic testing can only tell so much about breast cancer risk, however.
Treatment & Diagnosis
- Breast Cancer
- Breast Cancer Husband
- Breast Cancer: A Feisty Women's Discussion
- Inflammatory Breast Cancer
- Breast Cancer
- Breast Cancer: Mother-daughter relationships
- Breast Cancer: Early Diagnosis and Prevention
- Breast Cancer: Early Stage Treatments
- Breast Cancer: Clinical Trials - Today's Cutting Edge
- Breast Cancer, Metastatic: Treatment Goals and Therapy Options -- Harold J. Burstein, MD
- Breast Cancer, Taking Control: Self-Advocacy 101
- Breast Cancer: The Male View on Survival and Support
- Breast Cancer Treatment Update
- Breast Cancer FAQs
- Breast Cancer Risk - Reduced With Exercise
- Herceptin Metastatic Breast Cancer Treatment
- Breastfeeding -- Protection from Breast Cancer?
- Hormone Therapy in Survivors of Breast Cancer
- Breast Cancer: Types of Breast Cancer
- Exercise Improves Breast Cancer Survival
- Stress and Aggressive Breast Cancer: Cause or Effect?
- Advanced Breast Cancer in Young Women Increasing
- Angelina Jolie's Mastectomy
- Does Positive Additude Affect Breast Cancer?
- How Common and Dangerous Is Male Breast Cancer?
- How Many Breast Cancer Deaths Are there Each Year?
- Where Can Breast Cancer Spread To?
- Why Is Breast Cancer More Common in Females than Males?
- How Much Breast Cancer is Genetic?
- How Long Can Breast Cancer Patients Live?
- Who Does Breast Cancer Affect?
- How Does Breast Cancer Form?
- How Many Breast Cancer Stages Are There?
- Facts on Breast Cancer Causes, Risk Factors, and Types
- Breast Cancer Symptoms and Signs
- Breast Cancer Detection
- Breast Cancer Treatment
Medications & Supplements

Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.